Last update 30 May 2025

RG-7461

Overview

Basic Info

Drug Type
Antibody fusion proteins
Synonyms
Anti-fap/interleukin-2 fusion protein ro6874281, Simlukafusp alfa, AFAP-IL2V
+ [5]
Action
modulators, agonists
Mechanism
FAP modulators(Fibroblast activation protein alpha modulators), IL-2Rβγ agonists(Interleukin-2 Rβγ agonists), Immunomodulators
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cervical Squamous Cell CarcinomaPhase 2
United States
19 Feb 2018
Cervical Squamous Cell CarcinomaPhase 2
Belgium
19 Feb 2018
Cervical Squamous Cell CarcinomaPhase 2
France
19 Feb 2018
Cervical Squamous Cell CarcinomaPhase 2
Germany
19 Feb 2018
Cervical Squamous Cell CarcinomaPhase 2
Israel
19 Feb 2018
Cervical Squamous Cell CarcinomaPhase 2
New Zealand
19 Feb 2018
Cervical Squamous Cell CarcinomaPhase 2
Poland
19 Feb 2018
Cervical Squamous Cell CarcinomaPhase 2
Russia
19 Feb 2018
Cervical Squamous Cell CarcinomaPhase 2
Singapore
19 Feb 2018
Cervical Squamous Cell CarcinomaPhase 2
Spain
19 Feb 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Metastatic Cervical Squamous Cell Carcinoma
PD-L1 positive | PD-L1 negative
-
FAP-IL2v 10 mg Q3W
sofscfmrwq(ozhzytzssf) = davxjpxhzm iyhdwegvdt (ojnwurrfcj, 16.0 - 41.0)
Positive
01 Nov 2024
Phase 2
Esophageal Carcinoma
First line
PD-L1 Positive
34
FAP-IL2v 10atezolizumabzolizumab 1200 mg
diitqjysyn(ehfhqfjyix) = ewtqvvljrd etvegfocsw (adycssdhpj, 10.4 - 36.8)
Positive
06 May 2024
Phase 1
46
dwqmrohkas(skvajtmjru) = slxehoiejj gdrvzfzdgu (hpyzxjltue )
Negative
16 Sep 2021
Phase 2
-
yotxlkdxud(fgldbuudje) = tdrukdkdce vjwoshlmmp (odzdpqvebx, 18 - 39)
Positive
28 May 2021
Phase 1
69
myxasxvqhb(esrgpscfgd) = ucuzunwqnt wllcwxopue (lrppmeutuf, 12.95 - 40.12)
Positive
20 May 2021
myxasxvqhb(esrgpscfgd) = popwrxwerc wllcwxopue (lrppmeutuf, 27.67 - 66.68)
Phase 1
16
mjnkujkflc(bzpiximnbn) = mild or moderate cnshkjfdvs (bbsmstfiww )
Positive
20 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free